

The Daily

July 24, 2024







| HDFC securities | | 20 |
|-----------------|---------------|-------|
| Click. | Invest. Grow. | YEARS |

| DOMESTIC INDICES | | | | | | | |
|-----------------------|-------|------|-------|--|--|--|--|
| CLOSE POINTS % CHANGE | | | | | | | |
| SENSEX | 80429 | -73 | -0.09 | | | | |
| NIFTY | 24479 | -30 | -0.12 | | | | |
| MIDCAP | 46504 | -345 | -0.74 | | | | |
| SMALL CAP | 52823 | -93 | -0.18 | | | | |

| SECTORAL INDICES | | | | | | | |
|----------------------|-------|-------|-------|--|--|--|--|
| CLOSE POINTS % CHANG | | | | | | | |
| CD | 59036 | 1410 | 2.45 | | | | |
| IT | 40927 | 334 | 0.82 | | | | |
| HEALTHCARE | 38741 | 229 | 0.59 | | | | |
| TECK | 18672 | 104 | 0.56 | | | | |
| AUTO | 57265 | 109 | 0.19 | | | | |
| POWER | 7824 | -13 | -0.17 | | | | |
| METAL | 31534 | -325 | -1.02 | | | | |
| BANKEX | 59354 | -648 | -1.08 | | | | |
| FINANCE | 11349 | -146 | -1.27 | | | | |
| OIL & GAS | 30367 | -408 | -1.32 | | | | |
| CG | 71199 | -1479 | -2.03 | | | | |
| REALTY | 8330 | -183 | -2.15 | | | | |

| BSE 200 GAINERS/LOSERS | | | | | |
|------------------------|------------------|------------|-------|--|--|
| GAINERS | GAINERS % LOSERS | | | | |
| TITAN | 6.63 | RVNL | -5.33 | | |
| ITC | 5.52 | IRFC | -5.08 | | |
| SUZLON | 4.99 | MUTHOOTFIN | -4.25 | | |
| TATACONSUM | 4.49 | GICRE | -4.15 | | |
| TORNTPHARM | 4.20 | RECLTD | -3.88 | | |

| ADVANCE/DECLINES | | | | |
|------------------|------|----|--|--|
| BSE % | | | | |
| ADVANCES | 1743 | 43 | | |
| DECLINES | 2160 | 54 | | |
| UNCHANGED | 113 | 3 | | |

| INSTITUTIONAL ACTIVITY | | | | | | | |
|------------------------|----------------------------------|-------|-------|--|--|--|--|
| Rs Cr | 22-07-2024 23-07-2024 JULY TOTAI | | | | | | |
| FII | 3444 | -2975 | 22111 | | | | |
| DII | -1652 | 1419 | 7204 | | | | |

Indian markets could open mildly lower, in line with mostly lower Asian markets today and negative US markets on July 23

U.S. stocks finished lower on Tuesday as investors awaited earnings reports from Google parent Alphabet Inc. and electric-car maker Tesla Inc. after the closing bell. Small-cap stocks gained on Tuesday as a rotation out of megacap technology companies gathered more steam. In the kickoff to "Magnificent 7" earnings, Alphabet and Tesla both reported mixed quarterly results after the bell.

US two-year yields fell after a solid \$69 billion auction — which reflected market bets on rate cuts. Oil slumped amid algorithmic selling and low summer liquidity.

Vice President Kamala Harris is projected to have secured delegate backing to become the Democratic presidential nominee, helping settle any remaining nerves over President Joe Biden's withdrawal from the race. Kamala Harris opened up a marginal two-percentage-point lead over Republican Donald Trump after President Joe Biden ended his re-election campaign and passed the torch to her, a Reuters/Ipsos poll found. That compares with a marginal two-point deficit Biden faced against Trump in last week's poll before his Sunday exit from the race.

Most Asian stocks traded in narrow range mostly on the negative side on Wednesday following losses on Wall Street after an mediocre start to the earnings reports from the "Magnificent Seven" megacap technology companies.

The Indian market displayed high volatility on the day of Union Budget 2024 on 23rd July. Nifty ended the session with a minor fall of 0.12% and ended the session at 24479. Nifty managed to close above its 20 DMA support, placed at 24311 odd levels. On the higher side 24595 and 24855 could act as resistances, while 24074 becomes the new support for the Nifty.





BOVESPA

| 6¥ - | | | |
|-----------|--------|---------|----------|
| | | | |
| | GLOBAL | INDICES | |
| | CLOSE | POINTS | % CHANGE |
| DOW JONES | 40358 | -57.35 | -0.14 |
| S & P 500 | 5556 | -8.67 | -0.16 |
| NASDAQ | 19754 | -68.53 | -0.35 |
| FTSE | 8167 | -31.41 | -0.38 |
| CAC | 7599 | -23.39 | -0.31 |
| DAX | 18558 | 150.63 | 0.82 |
| NIKKEI | 39490 | -138.50 | -0.35 |
| SHANGHAI | 2911 | -4.72 | -0.16 |
| HANG SENG | 17416 | -53.36 | -0.31 |

| EXCHANGE RATES | | | | |
|----------------|-------|-------|--|--|
| VALUE % CHANGE | | | | |
| USD/INR | 83.7 | 0.20 | | |
| EURO/USD | 1.085 | -0.05 | | |
| USD/GBP | 1.289 | -0.09 | | |
| USD/JPY | 155.4 | -0.15 | | |

-1270.00


-0.99

126590

| COMMODITIES | | | | |
|----------------------------|--------|----------|--|--|
| | VALUE | % CHANGE | | |
| GOLD (\$ / Oz) | 2411.9 | 0.19 | | |
| SILVER (\$ / Oz) | 29.4 | 0.23 | | |
| CRUDE OIL FUTURES | 77.3 | 0.40 | | |
| BRENT OIL (\$ / Barrel) | 81.3 | 0.40 | | |

| BOND YIELD | | | |
|--------------------------|-------|------------|--|
| | VALUE | ABS CHANGE | |
| IND10 YEAR BOND YIELD | 6.970 | +0.003 | |

| ADR | | | | |
|----------------|-------|----------|--|--|
| | VALUE | % CHANGE | | |
| DR REDDY'S LAB | 80.9 | 1.04 | | |
| HDFC BANK | 60.5 | -0.38 | | |
| ICICI BANK | 29.1 | -0.85 | | |
| TATA MOTORS | 25.1 | 0.00 | | |
| WIPRO | 5.96 | -0.67 | | |
| VEDANTA LTD | 16.50 | 0.00 | | |
| INFOSYS | 22.08 | 1.33 | | |



HDFC securities

Invest, Grow,

One 97 Communications, which owns the brand Paytm, has partnered with Axis Bank to provide point-of-sales solutions and card payment machines to banks and its merchant network. Paytm's EDC devices (card machines) come equipped with integrated software that offers complete store management services, including inventory management, invoice generation, promotions and discounts, sales tracking and reporting, CRM, etc.

Titagarh Rail Systems Begins Export of Traction Converters with First Shipment to Italy

Titagarh Rail Systems Limited (TRSL) has commenced the export of traction converters, pursuant to which the first batch of 8 converters were shipped to Titagarh Firema S.p.A (Titagarh Firema), Italy. The said export is part of a EUR 7.18 million (Rs 65 crore) order received by TRSL from Titagarh Firema and marks the first rollout of traction converters from Passenger Rolling Stock Facility of Titagarh, India. Titagarh Firema received an order from Regione Lazio, Italy, for the design, manufacture and supply of 38 trainsets for a total value of approximately EUR 276 million, with a design speed of 100 kmph.

Jay Shree Tea & Industries executes agreement for sale of land for Rs. 100 crore

Jay Shree Tea & Industries Limited has entered into a definitive agreement for the sale of its 16.59 acres (more or less) freehold land at a consideration of Rs 100 crore on 'as is where is, basis situated at Plot no. 635 at Bohra Kalan Road Tehsil pataudi in the district of Gurugram, Haryana.

EDQM issued CEP Certificate for Valsartan

IOL Chemicals & Pharma said that European Directorate for the Quality of Medicines & Health Care (EDQM) has issued a Certificate of Suitability for Valsartan on 23rd July 2024. This certification will enable the Company to export this product in European and other CEP accepting countries. Valsartan is used for to treat high blood pressure (hypertension).







SpiceJet to raise up to Rs 3,000 crore via QIP

In a relief for low-cost carrier SpiceJet, the board of the budget carrier on Tuesday approved raising up to Rs 3,000 crore through a qualified institutional placement (QIP).

In December 2023, the SpiceJet board approved raising Rs 2,250 crore from 64 entities, including financial institutions, foreign institutional investors, high-net-worth individuals, and private investors through the issuance of equity shares and warrants. In February 2024, the airline said it secured additional funding of Rs 316 crore, bringing the total raised through its preferential issue to Rs 1,060 crore.

Bajel Projects received an order worth Rs 586 crore

Bajel Projects received an order worth Rs 586 crore through Tariff Based Competitive Bidding (TBCB) route from PowerGrid Corporation of India Limited (PGCIL). It is for Transmission Line Package TL01 for 765 kV D/c Beawar – Mandsaur PS Transmission Line – Part I associated with "Transmission System for evacuation of power from Rajasthan REZ Ph-IV (Part-2: 5.5GW) (Jaisalmer/ Barmer Complex). The project is likely to get executed in the next 23 months.

Gland Pharma received tentative approval from the US FDA for Latanoprostene Bunod Ophthalmic Solution

Gland Pharma Limited has received tentative approval from the United States Food and Drug Administration (US FDA) for Latanoprostene Bunod Ophthalmic Solution, 0.024%. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vyzulta Ophthalmic Solution, 0.024%, registered by Bausch & Lomb Inc.

Company believes that it is the first applicant to have filed its ANDA with Para IV certification. Upon final approval, the company may be eligible for 180 days of generic drug exclusivity. It is indicated for reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. According to IQVIA, the product had US sales of approximately US\$ 153 million for the twelve months ended December 2023.

Zydus Lifesciences received final approval from US FDA for Valsartan Tablets

Zydus Lifesciences Limited has received final approval from the US FDA to market Valsartan Tablets USP, 40 mg, 80 mg, 160 mg and 320 mg (USRLD: Diovan tablets). Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and paediatric patients one year of age and older.

Valsartan tablets had annual sales of US\$ 149.5mn in the United States (IQVIA MAT May 2024).

CEAT lines up Rs 1000 crore capex in FY25, flags margin woes

CEAT Ltd. has outlined a capital expenditure of Rs 1,000 crore for the current fiscal even as it sees margin pressure continuing for another quarter due to consistent increase in the price of natural rubber.

Rushil Decor expands into the North American Market

Rushil Decor Ltd. is expanding its presence into the North American market, marking a significant milestone in its global growth strategy. Rushil Decor already reaching over 50 countries, aims to capitalize on one of the world's largest markets for Laminates and MDF.







Hindustan Unilever Q1FY25 Result Review

Consolidated Net Revenue from operations stood at Rs. 15,707 cr; up by 1.4% YoY as against Rs. 15,496 cr in Q1FY24, growth driven by 4% underlying volume growth (UVG). EBITDA at Rs. 3,744 cr in Q1FY25 grew 2.2% YoY, as compared to Rs. 3,665 cr in Q1FY24 PAT was up by 1.6% YoY to Rs 2,610 cr as against Rs 2,568 cr in Q1FY24. Gross margin expanded by 152 bps YoY, at 52.0% in Q1FY25 with continued moderation in input costs.

Segment contribution from Homecare/Beauty & Wellbeing/Personal Care/Foods & Refreshment/Others stood at 36%/21%/15%/25%/3% in Q1FY25.

Homecare Segment reported 4.6% YoY growth in with EBIT margin of 20.0% with UVG for the segment in high single digits. Fabric wash registered high-single digit volume growth and broad-based performance across segments and formats led by investments in premium and mass brands. Household Care volumes grew in mid-single digit on the back of strong performance by premium dishwash portfolio.

Beauty & Wellbeing Segment revenue was up by 3.5% YoY on the back of mid-single digit UVG. Hair Care witnessed double-digit volume growth led by Clinic Plus, Sunsilk and Dove. Skin care and colour cosmetics however, witnessed muted volume performance with mass portfolio declining. EBIT margin for the segment stood at 30.5%

Personal Care Segment witnessed 4.5% decline in revenue due to pricing actions while UVG growth in low single digits. EBIT margin for the segment stood at 17.8%.

Foods & Refreshment Segment reported 1.4% YoY growth, with segment volume growth being flat in Q1FY25. Segment's reported EBIT margin of 19.1%. Tea continued to cement its market leadership through value and volume share gains. Coffee grew in double digits driven by pricing and strong growth in channels of the future. Nutrition drinks registered subdued performance during the quarter.

United Spirits Q1FY25 Result Review

Consolidated Net Revenue from operations stood at Rs. 2,761 cr; up by 3.5% YoY as against Rs. 2,667 cr in Q1FY24, driven by improved footprint & saliency of our innovation and renovation offerings and revenue growth management interventions. EBITDA came in at Rs. 713 cr in Q1FY25, flat on a YoY basis while PAT was up 1.7% YoY to Rs 485 cr as against Rs 477 cr in Q1FY24.

Overall volume increased 3.5% YoY to 13,699,000 cases in Q1FY25 as compared to 13,241,000 cases in Q1FY24.

Prestige & Above segment's net sales increased 10.1% during the first quarter, with volume growth in the segment coming in at 5.1% YoY. The segment accounted for 87.8% of net sales during the first quarter.

Popular segment's net sales fell by 2.4% YoY on account of a 4.6% YoY decline in volumes as inflation continues to impact the price sensitive consumer of this segment. The segment accounted for 9.4% of net sales.

The company's renovation and innovation offerings are rolling out progressively with an encouraging response and it remains focused on enhancing the long-term competitiveness of its portfolio.







Bajaj Finance Q1FY25 Result update

Bajaj Finance reported 14% YoY growth in consolidated net profit to Rs 3,912 crore. Net interest income (NII) grew 25% on-year to Rs 8,365 crore. Assets under management expanded 31 percent on-year to Rs 3.5 lakh crore at the end of the quarter. Loan losses and provisions for the April-June 2024 period rose to Rs 1,685 crore, compared to Rs 995 crore in the corresponding period of the previous year. Gross NPA and net NPA as of non-bank lender stood at 0.86%/0.38% against 0.85%/0.37% in Q4FY24.

During the first quarter, the number of new loans issued increased by 10 per cent to 10.97 million. The customer base reached 88.11 million by the end of June 2024, up from 72.98 million in June 2023, reflecting a 21 per cent growth. The company resumed the sanctioning and disbursal of loans under 'eCOM' and 'Insta EMI Card' and began issuing EMI cards again after the RBI lifted restrictions on these activities in May.

M&M Financial Q1FY25 Result update

M&M Financial Services reported a standalone PAT of Rs 513 crore for Q1FY25, a growth of 45% YoY. Net interest income (NII) was reported at Rs 1,932 crore in the reported quarter, up by 15%. The standalone Pre-Provisioning Operating Profit (PPOP) was reported at Rs 1,135 crore, up 13%.

The company managed to bring down its credit costs in the April-June quarter to Rs 448 crore from Rs 526 crore in Q1FY24, recording 15% decline. Gross loan book stood at Rs 1,06,339 crore at the end of June 30, 2024, up 23% YoY. GNPA/NNPA increased sequentially by 20 bps to 3.6%/1.5%.

Torrent Pharma Q1FY25 result update

Revenue for the quarter grew 10.3% YoY at Rs 2859cr as against expectation of Rs 2891cr. EBITDA margin improved 110bps YoY at 31.6% as against estimate of 31.5%. Net profit increased 20.9% YoY at Rs 457cr. Finance cost declined 27.2% YoY at Rs 75cr.

India business registered 15% YoY growth at Rs 1635cr. US sales declined 12% YoY at Rs 259cr. Germany business increased 10% YoY at Rs 284cr.

EPS for the quarter stood at Rs 13.5 and it was at Rs 48.94 for FY24. At CMP, the stock trades at 42.5x FY26E EPS.

Sharda Cropchem Q1FY25 result update

Overall numbers witnessed improvement on YoY basis on low base effect, and came in almost in-line with estimates. Total revenue grew 23% YoY at Rs 785cr as against expectation of Rs 768cr. EBITDA stood at Rs 77cr as against loss of Rs 59cr, a year ago. Adj. EBITDA stood at Rs 88.3cr as against loss of Rs 66cr. Gross margin stood at 29.2% vs. 8.7% on YoY basis. Net profit came in at Rs 27.3cr as against net loss of Rs 88.6cr. Other Income declined 26% YoY at Rs 19.3cr.

Agrochemical sales increased 43% YoY at Rs 679cr. Non-agrochemicals revenue declined 35% YoY at Rs 106cr.

Sharda has procured 2,928 registrations as on Jun-2024. Additionally, it has filed 1,039 applications for registrations globally pending at different stages.

EPS for the quarter stood at Rs 3.02. At CMP, the stock trades at 17.5x FY26E EPS.







DCM Shriram Q1FY25 result update

Revenue for the quarter grew 4.6% YoY at Rs 3073cr. EBITDA margin improved 250bps YoY at 8.1%. Net profit was up 77% YoY at Rs 100.3cr. Other Income was up 49% YoY at Rs 25.9cr.

Chloro Vinyl segment grew 15% YoY at Rs 805cr. Sugar business remained flat YoY at Rs 956cr. Shriram Farm Solutions revenue grew 15% YoY at Rs 271cr.

The capex in Chemical business is nearing completion. Hydrogen Peroxide Plant has started trial runs and EpiChloroHydrin (ECH) plant is expected to start trial runs by Q2FY25. Expansion of sugar capacity and CBG project in Sugar business are progressing as per schedule.

Important news/developments to influence markets

China adds 6.98 million urban new jobs in first half of year

China said that it added 6.98 million urban new jobs in the first half of the year, according to the human resources ministry. The ministry also said the "employment situation is generally stable", and that it will push for the return of stable jobs and special loans for job stabilization and expansion.

German tax revenue rose 6.2% in June

Germany's federal and regional state governments' tax revenue rose strongly in June compared with the same month last year, the finance ministry said.







| Index | СМР | View | R1 | R2 | S1 | S2 |
|------------------------|-------|---------------|-------|-------|-------|-------|
| Nifty July Future | 24453 | Consolidation | 24565 | 24660 | 24320 | 24205 |
| Bank Nifty July Future | 51765 | Negative | 52225 | 52670 | 51280 | 50870 |





Daily Technical View on Nifty

High volatility on the budget day..

Observation: After showing downward correction from the new highs recently, Nifty witnessed high volatility on Tuesday (Union Budget 2024)and closed the day lower by 30 points.

After opening with a positive note, the market slipped into minor weakness till 11 am on Tuesday. During presentation of Union Budget in the Parliament in the afternoon Nifty slipped into sharp weakness and recovered quickly from the day's low. Finally closed the day off the lows.

A small negative candle was formed on the daily chart with long lower shadow. Technically, this pattern indicates a formation of bullish hammer type candle pattern and this signals an attempt of comeback of bulls from the lower levels. A sustainable upmove from here could confirm short term reversal pattern on the upside.

The market continued to sustain above daily 10- and 20-day EMA. Nifty has been sustaining above these moving averages since past 5-6 weeks and have formed few minor bottom reversals around these supports in the past.

Conclusion: The short term trend of Nifty remains negative with high volatility. Emergence of sharp buying and the formation of positive candle pattern on Tuesday is signaling occurrence of bullish reversal pattern in the coming sessions.

A sustainable move above 24650-24700 could open the next upside towards 24850-24900 levels in the near term. Crucial lower support is at 24100 levels.







OPEN E-MARGIN POSITIONAL CALLS

| NO. | RECO DT. | RECO | COMPANY NAME | ENTRY | СМР | SL | TARGET 1 | TARGET 2 | UPSIDE % | VALID TILL |
|-----|-----------|------|--------------|-------------------|--------|--------|----------|----------|----------|------------|
| 1 | 14-JUN-24 | BUY | STAR | 947-890 | 985.0 | 870.0 | 1045.0 | 1090.0 | 11 | 14-SEP-24 |
| 2 | 3-JUL-24 | BUY | IPCA LAB* | 1155-1114 | 1241.2 | 1155.0 | 1240.0 | 1305.0 | 5 | 3-SEP-24 |
| 3 | 16-JUL-24 | BUY | INDIAN BANK | 580-555 | 552.4 | 540.0 | 625.0 | 665.0 | 20 | 16-SEP-24 |
| 4 | 16-JUL-24 | BUY | HIL | 2979.5- 2757.5 | 3005.8 | 2677.5 | 3519.5 | 3577.5 | 19 | 16-OCT-24 |

*= 1st Target Achieved







The Daily

QUARTERLY RESULTS ANNOUNCED

| COMPANY | Q1F | Y25 | ΥΟΥ | (%) | QOQ (%) | | REMARK | |
|-----------------------|---------------|------------|-------|------|---------|-------|--|--|
| | SALES (RS CR) | NP (RS CR) | SALES | NP | SALES | NP | REWARK | |
| Torrent Pharma | 2859 | 457.0 | 10.3 | 20.9 | 4.2 | 1.8 | In-line with estimates | |
| Sharda Cropchem | 785 | 27.3 | 23.0 | - | -39.5 | -81.0 | In-line with estimates | |
| Bajaj Finance | 8365.3 | 3912.0 | -0.4 | 13.8 | 4.4 | 2.3 | As per expectations | |
| M&M Fin. | 1783.6 | 513.0 | 12.6 | 45.5 | -1.6 | -17.1 | As per expectations | |
| Hindustan Unilever | 15707 | 2610 | 1.4 | 1.6 | 3.3 | 2.0 | Revenue in-line and PAT above Expectations | |
| United Spirits | 2761.0 | 485.0 | 3.5 | 1.7 | -0.8 | 101.2 | Revenue and PAT in-line with Expectations | |







Disclaimer:

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report. As regards the associates of HSL please refer the website.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.







HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

Please note that HDFC Securities has a proprietary trading desk. This desk maintains an arm's length distance with the Research team and all its activities are segregated from Research activities. The proprietary desk operates independently, potentially leading to investment decisions that may deviate from research views.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066

Compliance Officer: Murli V Karkera Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

For grievance redressal contact Customer Care Team Email: customercare@hdfcsec.com Phone: (022) 3901 9400 HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI

Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing.

Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.



#HDFCsecMythBusters





Scan the code to download our mobile app now!

Global Investing, Basket Investing are not a Exchange traded product and all disputes related to the distribution activity of Global Investing and Basket Investing will not have access to Exchange investor redressal forum or Arbitration mechanism. Involvement of HDFC securities is restricted to Referral only. HDFC securities does not offer this product directly to customers https://www.hdfcsec.com/globalinvesting. Account would be opened after all procedure relating to IPV and client due diligence is completed. Investment in securities market are subject to market risks, read all the related documents carefully before investing. SEBI registration & disclaimers: https://www.hdfcsec.com/article/disclaimer-1795. The information is only for consumption by the client and such material should not be redistributed.